Production of influenza pseudotyped lentiviral particles and their use in influenza research and diagnosis: An update

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 4, 2011, Pages 443-455

  Garcia, Jean Michel ^a   Lai, Jimmy Cc ^a  

^a HKU PASTEUR RESEARCH CENTRE   (Hong Kong)

Author keywords

characterization; diagnostics; influenza; neutralization assay; production; pseudoparticles; pseudotyped lentiviral particle

Indexed keywords

ANTIVIRUS AGENT; CELL SURFACE PROTEIN; PROTEIN M2; PROTEINASE; SIALIDASE; VIRUS HEMAGGLUTININ;

DRUG SCREENING; EX VIVO GENE TRANSFER; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; IN VIVO GENE TRANSFER; INFLUENZA; INFLUENZA VIRUS; LENTIVIRINAE; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NONHUMAN; PLASMID; PROTEIN PROTEIN INTERACTION; PSEUDOTYPED LENTIVIRUS PARTICLE; PSEUDOTYPING; RECEPTOR BINDING; REVIEW; SERODIAGNOSIS; VIRUS ATTACHMENT; VIRUS CHARACTERIZATION; VIRUS CONCENTRATION; VIRUS ENTRY; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS TITRATION;

ANIMALS; BIRD DISEASES; BIRDS; CHIMERA; DRUG DISCOVERY; HUMANS; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; INFLUENZAVIRUS A; LENTIVIRUS; MEMBRANE GLYCOPROTEINS; MOLECULAR BIOLOGY; ORTHOMYXOVIRIDAE INFECTIONS; PLASMIDS; SWINE; SWINE DISEASES; TRANSFECTION; VIRAL PROTEINS; VIRION;

EID: 79955085527     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.25     Document Type: Review

References (136)

1. Taubenberger JK, Morens DM. Influenza: the once and future pandemic. Public Health Rep. 125(Suppl. 3), 16-26 (2010).
2. Bouvier NM, Palese P. The biology of influenza viruses. Vaccine 26(Suppl. 4), D49-D53 (2008).
3. Dugan VG, Chen R, Spiro DJ et al. The evolutionary genetics and emergence of avian influenza viruses in wild birds. PLoS Pathog. 4(5), e1000076 (2008).
4. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol. Rev. 56(1), 152-179 (1992).
5. Alexander DJ. Avian influenza viruses and human health. Dev. Biol. (Basel) 124, 77-84 (2006). (Pubitemid 43258902)
6. Kalthoff D, Globig A, Beer M. (Highly pathogenic) avian influenza as a zoonotic agent. Vet. Microbiol. 140(3-4), 237-245 (2010).
7. Malik Peiris JS. Avian influenza viruses in humans. Rev. Sci. Tech. 28(1), 161-173 (2009).
8. Huang AS, Palma EL, Hewlett N, Roizman B. Pseudotype formation between enveloped RNA and DNA viruses. Nature 252(5485), 743-745 (1974).
9. Rubin H. Genetic control of cellular susceptibility to pseudotypes of rous sarcoma virus. Virology 26, 270-276 (1965).
10. Zavada J, Rosenbergova M. Phenotypic mixing of vesicular stomatitis virus with fowl plague virus. Acta. Virol. 16(2), 103-114 (1972).
11. Frecha C, Szecsi J, Cosset FL, Verhoeyen E. Strategies for targeting lentiviral vectors. Curr. Gene Ther. 8(6), 449-460 (2008).
12. Verhoeyen E, Cosset FL. Engineering the surface glycoproteins of lentiviral vectors for targeted gene transfer. Cold Spring Harb. Protoc. DOI:10.1101/pdb.top59 (2009) (Epub ahead of print).
13. Bright RA, Carter DM, Crevar CJ et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 3(1), e1501 (2008).
14. Ross TM, Mahmood K, Crevar CJ, Schneider-Ohrum K, Heaton PM, Bright RA. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS ONE 4(6), e6032 (2009).
15. Wu Q, Fang L, Wu X et al. A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens. Mol. Immunol. 46(11-12), 2210-2217 (2009).
16. Dong J, Roth MG, Hunter E. A chimeric avian retrovirus containing the influenza virus hemagglutinin gene has an expanded host range. J. Virol. 66(12), 7374-7382 (1992).
17. Baum C, Schambach A, Bohne J, Galla M. Retrovirus vectors: toward the plentivirus? Mol. Ther. 13(6), 1050-1063 (2006).
18. McKay T, Patel M, Pickles RJ, Johnson LG, Olsen JC. Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors. Gene Ther. 13(8), 715-724 (2006).
19. Oh S, Selleck P, Temperton NJ et al. Neutralizing monoclonal antibodies to different clades of Influenza A H5N1 viruses. J. Virol. Methods 157(2), 161-167 (2009).
20. Su CY, Wang SY, Shie JJ et al. In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses. Antiviral Res. 79(3), 199-205 (2008).
21. Szecsi J, Boson B, Johnsson P et al. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol. J. 3, 70 (2006).
22. Wang SY, Su CY, Lin M et al. HA-pseudotyped retroviral vectors for influenza antagonist screening. J. Biomol. Screen. 14(3), 294-302 (2009).
23. Hanika A, Larisch B, Steinmann E, Schwegmann-Wessels C, Herrler G, Zimmer G. Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes. J. Gen. Virol. 86(Pt 5), 1455-1465 (2005). (Pubitemid 40613264)
24. Ito H, Watanabe S, Takada A, Kawaoka Y. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J. Virol. 75(3), 1576-1580 (2001). (Pubitemid 32094718)
25. Matsuno K, Kishida N, Usami K et al. Different potential of C-type lectin-mediated entry between Marburg virus strains. J. Virol. 84(10), 5140-5147 (2010).
26. Roth MG, Compans RW. Delayed appearance of pseudotypes between vesicular stomatitis virus influenza virus during mixed infection of MDCK cells. J. Virol. 40(3), 848-860 (1981). (Pubitemid 12247262)
27. Bupp K, Gonzalez-Scarano F. Pseudotype formation with La Crosse virus glycoproteins. J. Gen. Virol. 79(Pt 4), 667-671 (1998). (Pubitemid 28161938)
28. Mayrhofer J, Coulibaly S, Hessel A et al. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. J. Virol. 83(10), 5192-5203 (2009).
29. Briggs JA, Wilk T, Fuller SD. Do lipid rafts mediate virus assembly and pseudotyping? J. Gen. Virol. 84(Pt 4), 757-768 (2003). (Pubitemid 36432205)
30. Pickl WF, Pimentel-Muinos FX, Seed B. Lipid rafts and pseudotyping. J. Virol. 75(15), 7175-7183 (2001). (Pubitemid 32641605)
31. Sandrin V, Cosset FL. Intracellular versus cell surface assembly of retroviral pseudotypes is determined by the cellular localization of the viral glycoprotein, its capacity to interact with Gag, and the expression of the Nef protein. J. Biol. Chem. 281(1), 528-542 (2006). (Pubitemid 43671216)
32. Ali A, Avalos RT, Ponimaskin E, Nayak DP. Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein. J. Virol. 74(18), 8709-8719 (2000). (Pubitemid 30666721)
33. Chen BJ, Leser GP, Jackson D, Lamb RA. The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding. J. Virol. 82(20), 10059-10070 (2008).
34. Nayak DP, Balogun RA, Yamada H, Zhou ZH, Barman S. Influenza virus morphogenesis and budding. Virus Res. 143(2), 147-161 (2009).
35. Radyukhin V, Fedorova N, Ksenofontov A, Serebryakova M, Baratova L. Cold co-extraction of hemagglutinin and matrix M1 protein from influenza virus A by a combination of non-ionic detergents allows for visualization of the raft-like nature of the virus envelope. Arch. Virol. 153(10), 1977-1980 (2008).
36. Hammarstedt M, Garoff H. Passive and active inclusion of host proteins in human immunodeficiency virus type 1 gag particles during budding at the plasma membrane. J. Virol. 78(11), 5686-5697 (2004). (Pubitemid 38661656)
37. Kueng HJ, Schmetterer KG, Pickl WF. Lipid rafts, pseudotyping, and virus-like particles: relevance of a novel, configurable, and modular antigen-presenting platform. Int. Arch. Allergy Immunol. 154(2), 89-110 (2010).
38. Leung K, Kim JO, Ganesh L, Kabat J, Schwartz O, Nabel GJ. HIV-1 assembly: viral glycoproteins segregate quantally to lipid rafts that associate individually with HIV-1 capsids and virions. Cell Host Microbe 3(5), 285-292 (2008). (Pubitemid 351636000)
39. Yue L, Shang L, Hunter E. Truncation of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein defines elements required for fusion, incorporation, and infectivity. J. Virol. 83(22), 11588-11598 (2009).
40. Bischof D, Cornetta K. Flexibility in cell targeting by pseudotyping lentiviral vectors. Methods Mol. Biol. 614, 53-68 (2010).
41. Kim SH, Jang SI, Park CY, You JC. Investigation of requirements for efficient gene delivery using the HIV-1 based lentiviral transduction system. Biochem. Biophys. Res. Commun. 383(2), 192-197 (2009).
42. Lewis P, Hensel M, Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J. 11(8), 3053-3058 (1992).
43. Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. 68(1), 510-516 (1994).
44. Hatziioannou T, Valsesia-Wittmann S, Russell SJ, Cosset FL. Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses. J. Virol. 72(6), 5313-5317 (1998). (Pubitemid 28215721)
45. Temperton NJ, Hoschler K, Major D et al. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respi. Viruses 1(3), 105-112 (2007).
46. Barde I, Salmon P, Trono D. Production and titration of lentiviral vectors. Curr. Protoc. Neurosci. Chapter 4, Unit 4 21 (2010).
47. Temperton N, Wright E. Retroviral pseudotypes. In: Encyclopedia of Life Sciences. John Wiley & Sons, Ltd., Chichester, UK. DOI: 10.1002/ 9780470015902.a0021549 (2009).
48. Baker M. Biochemistry. Hidden code in the protein code. Nat. Methods 7(11), 874 (2010).
49. Ohuchi M, Cramer A, Vey M, Ohuchi R, Garten W, Klenk HD. Rescue of vector-expressed fowl plague virus hemagglutinin in biologically active form by acidotropic agents and coexpressed M2 protein. J. Virol. 68(2), 920-926 (1994). (Pubitemid 24022195)
50. Corti D, Suguitan AL Jr, Pinna D et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120(5), 1663-1673 (2010).
51. Lin AH, Cannon PM. Use of pseudotyped retroviral vectors to analyze the receptor-binding pocket of hemagglutinin from a pathogenic avian influenza A virus (H7 subtype).Virus Res. 83(1-2), 43-56 (2002). (Pubitemid 34183375)
52. Szecsi J, Gabriel G, Edfeldt G, Michelet M, Klenk HD, Cosset FL. DNA vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian influenza A virus. J. Infect. Dis. 200(2), 181-190 (2009).
53. Bosch V, Kramer B, Pfeiffer T, Starck L, Steinhauer DA. Inhibition of release of lentivirus particles with incorporated human influenza virus haemagglutinin by binding to sialic acid-containing cellular receptors. J. Gen. Virol. 82(Pt 10), 2485-2494 (2001). (Pubitemid 32936781)
54. Ao Z, Patel A, Tran K et al. Characterization of a trypsin-dependent avian influenza H5N1-pseudotyped HIV vector system for high throughput screening of inhibitory molecules. Antiviral Res. 79(1), 12-18 (2008).
55. Wang W, Castelan-Vega JA, Jimenez- Alberto A, Vassell R, Ye Z, Weiss CD. A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity. Virology 407(2), 374-380 (2010).
56. Thorne N, Inglese J, Auld DS. Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. Chem. Biol. 17(6), 646-657 (2010).
57. Olesen CE, Yan YX, Liu B et al. Novel methods for chemiluminescent detection of reporter enzymes. Methods Enzymol. 326, 175-202 (2000).
58. Karolewski BA, Watson DJ, Parente MK, Wolfe JH. Comparison of transfection conditions for a lentivirus vector produced in large volumes. Hum. Gene Ther. 14(14), 1287-1296 (2003). (Pubitemid 37174753)
59. Tom R, Bisson L, Durocher Y. Transfection of HEK293-EBNA1 cells in suspension with linear PEI for production of recombinant proteins. Cold Spring Harb. Protoc. DOI:10.1101/ pdb.prot4977 (2008).
60. Jordan M, Schallhorn A, Wurm FM. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res. 24(4), 596-601 (1996). (Pubitemid 26085833)
61. Salmon P, Trono D. Production and titration of lentiviral vectors. Curr. Protoc. Hum. Genet. 12(12), 10 (2007).
62. Bertram S, Glowacka I, Steffen I, Kuhl A, Pohlmann S. Novel insights into proteolytic cleavage of influenza virus hemagglutinin. Rev. Med. Virol. 20(5), 298-310 (2010).
63. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569 (2000).
64. Bottcher-Friebertshauser E, Freuer C, Sielaff F et al. Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors. J. Virol. 84(11), 5605-5614 (2010).
65. Wang W, Butler EN, Veguilla V et al. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J. Virol. Methods 153(2), 111-119 (2008).
66. Bottcher E, Freuer C, Steinmetzer T, Klenk HD, Garten W. MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition. Vaccine 27(45), 6324-6329 (2009).
67. Kutner RH, Puthli S, Marino MP, Reiser J. Simplified production and concentration of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange membrane chromatography. BMC Biotechnol. 9, 10 (2009).
68. Kutner RH, Zhang XY, Reiser J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat. Protoc. 4(4), 495-505 (2009).
69. Olsen JC, Sechelski J. Use of sodium butyrate to enhance production of retroviral vectors expressing CFTR cDNA. Hum. Gene Ther. 6(9), 1195-1202 (1995).
70. Ellis BL, Potts PR, Porteus M. Creating higher titer lentivirus using caffeine. Hum. Gene Ther. 22(1), 93-100 (2010).
71. Godbey WT, Wu KK, Hirasaki GJ, Mikos AG. Improved packing of poly(ethylenimine)/DNA complexes increases transfection efficiency. Gene Ther. 6(8), 1380-1388 (1999). (Pubitemid 29396726)
72. Ulasov AV, Khramtsov YV, Trusov GA, Rosenkranz AA, Sverdlov ED, Sobolev AS. Properties of PEI-based polyplex nanoparticles that correlate with their transfection efficacy. Mol. Ther. 1, 103-112 (2010).
73. Yue Y, Jin F, Deng R et al. Revisit complexation between DNA and polyethylenimine - effect of uncomplexed chains free in the solution mixture on gene transfection. J. Control. Release DOI:10.1016/j.jconrel.2010.10.028 (2010) (Epub ahead of print).
74. Ren Y, Jiang X, Pan D, Mao HQ. Charge density and molecular weight of polyphosphoramidate gene carrier are key parameters influencing its DNA compaction ability and transfection efficiency. Biomacromolecules 11(12), 3432-3439 (2010).
75. Amorij JP, Meulenaar J, Hinrichs WL et al. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 25(35), 6447-6457 (2007). (Pubitemid 47198923)
76. Wei CJ, Boyington JC, Dai K et al. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci. Transl. Med. 2(24), 24ra21 (2010).
77. Geraerts M, Willems S, Baekelandt V, Debyser Z, Gijsbers R. Comparison of lentiviral vector titration methods. BMC Biotechnol. 6, 34 (2006).
78. Sastry L, Johnson T, Hobson MJ, Smucker B, Cornetta K. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther. 9(17), 1155-1162 (2002). (Pubitemid 34993938)
79. Transfiguracion J, Coelho H, Kamen A. High-performance liquid chromatographic total particles quantification of retroviral vectors pseudotyped with vesicular stomatitis virus-G glycoprotein. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 813(1-2), 167-173 (2004). (Pubitemid 39535443)
80. Nefkens I, Garcia JM, Ling CS et al. Hemagglutinin pseudotyped lentiviral particles: characterization of a new method for avian H5N1 influenza sero-diagnosis. J. Clin. Virol. 39(1), 27-33 (2007). (Pubitemid 46575342)
81. Wang W, Xie H, Ye Z, Vassell R, Weiss CD. Characterization of lentiviral pseudotypes with infH5N1 hemagglutinin and their performance in neutralization assays. J. Virol. Methods 165(2), 305-310 (2010).
82. Escors D, Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch. Immunol. Ther. Exp. (Warsz.) 58(2), 107-119 (2010).
83. Matrai J, Chuah MK, VandenDriessche T. Recent advances in lentiviral vector development and applications. Mol. Ther. 18(3), 477-490 (2010).
84. Duisit G, Conrath H, Saleun S et al. Five recombinant simian immunodeficiency virus pseudotypes lead to exclusive transduction of retinal pigmented epithelium in rat. Mol. Ther. 6(4), 446-454 (2002). (Pubitemid 35214865)
85. Mohan S, McAtamney S, Haselhorst T, von Itzstein M, Pinto BM. Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles. J. Med. Chem. 53(20), 7377-7391 (2010).
86. Song G, Yang S, Zhang W et al. Discovery of the first series of small molecule H5N1 entry inhibitors. J. Med. Chem. 52(23), 7368-7371 (2009).
87. Suzuki Y, Ito T, Suzuki T et al. Sialic acid species as a determinant of the host range of influenza A viruses. J. Virol. 74(24), 11825-11831 (2000). (Pubitemid 32222332)
88. Viswanathan K, Chandrasekaran A, Srinivasan A, Raman R, Sasisekharan V, Sasisekharan R. Glycans as receptors for influenza pathogenesis. Glycoconj. J. 27(6), 561-570 (2010).
89. Zhang H. Tissue and host tropism of influenza viruses: importance of quantitative analysis. Sci. China C Life Sci. 52(12), 1101-1110 (2009).
90. Suzuki Y. Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses. Biol. Pharm. Bull. 28(3), 399-408 (2005). (Pubitemid 40879958)
91. Nicholls JM, Chan RW, Russell RJ, Air GM, Peiris JS. Evolving complexities of influenza virus and its receptors. Trends Microbiol. 16(4), 149-157 (2008).
92. Joo KI, Wang P. Visualization of targeted transduction by engineered lentiviral vectors. Gene Ther. 15(20), 1384-1396 (2008).
93. Muthumani K, Montaner LJ, Ayyavoo V, Weiner DB. Vpr-GFP virion particle identifies HIV-infected targets and preserves HIV-1Vpr function in macrophages and T-cells. DNA Cell. Biol. 19(3), 179-188 (2000). (Pubitemid 30174154)
94. Haselhorst T, Garcia JM, Islam T et al. Avian influenza H5-containing virus-like particles (VLPs): host-cell receptor specificity by STD NMR spectroscopy. Angew. Chem. Int. Ed. Engl. 47(10), 1910-1912 (2008).
95. Su Y, Zhu X, Wang Y, Wu M, Tien P. Evaluation of Glu11 and Gly8 of the H5N1 influenza hemagglutinin fusion peptide in membrane fusion using pseudotype virus and reverse genetics. Arch. Virol. 153(2), 247-257 (2008).
96. Huang IC, Li W, Sui J, Marasco W, Choe H, Farzan M. Influenza A virus neuraminidase limits viral superinfection. J. Virol. 82(10), 4834-4843 (2008). (Pubitemid 351657045)
97. Su B, Wurtzer S, Rameix-Welti MA et al. Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA).PLoS ONE 4(12), e8495 (2009).
98. Joo KI, Tai A, Lee CL, Wong C, Wang P. Imaging multiple intermediates of single-virus membrane fusion mediated by distinct fusion proteins. Microsc. Res. Tech. 73(9), 886-900 (2010).
99. Zhang Y, Lin X, Wang G et al. Neuraminidase and hemagglutinin matching patterns of a highly pathogenic avian and two pandemic H1N1 influenza A viruses. PLoS ONE 5(2), e9167 (2010).
100. Zhang Y, Lin X, Zhang F et al. Hemagglutinin and neuraminidase matching patterns of two influenza A virus strains related to the 1918 and 2009 global pandemics. Biochem. Biophys. Res. Commun. 387(2), 405-408 (2009).
101. Du N, Zhou J, Lin X et al. Differential activation of NK cells by influenza A pseudotype H5N1 and 1918 and 2009 pandemic H1N1 viruses. J. Virol. 84(15), 7822-7831 (2010).
102. Ho JW, Hershkovitz O, Peiris M et al. H5-type influenza virus hemagglutinin is functionally recognized by the natural killer-activating receptor NKp44. J. Virol. 82(4), 2028-2032 (2008). (Pubitemid 351206948)
103. Zhang S, Xiao L, Zhou H et al. Generation and characterization of an H5N1 avian influenza virus hemagglutinin glycoprotein pseudotyped lentivirus. J. Virol. Methods 154(1-2), 99-103 (2008).
104. Haynes JR, Dokken L, Wiley JA et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 27(4), 530-541 (2009).
105. Haynes JR. Influenza virus-like particle vaccines. Expert Rev. Vaccines 8(4), 435-445 (2009).
106. Du L, Zhao G, Zhang X et al. Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies. Biochem. Biophys. Res. Commun. 397(3), 580-585 (2010).
107. Alberini I, Del Tordello E, Fasolo A et al. Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 27(43), 5998-6003 (2009).
108. Garcia JM, Pepin S, Lagarde N et al. Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin. PLoS ONE 4(11), e7918 (2009).
109. Labrosse B, Tourdjman M, Porcher R et al. Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 influenza viruses using a pseudotype neutralization assay. PLoS ONE 5(6), e11036 (2010).
110. Chen MW, Cheng TJ, Huang Y et al. A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc. Natl Acad. Sci. USA 105(36), 13538-13543 (2008).
111. Rao S, Kong WP, Wei CJ et al. Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. PLoS ONE 3(6), e2432 (2008).
112. Rao SS, Kong WP, Wei CJ et al. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS ONE 5(3), e9812 (2010).
113. Shen S, Mahadevappa G, Oh HL et al. Comparing the antibody responses against recombinant hemagglutinin proteins of avian influenza A (H5N1) virus expressed in insect cells and bacteria. J. Med. Virol. 80(11), 1972-1983 (2008).
114. Tsai C, Caillet C, Hu H et al. Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. Vaccine 27(48), 6777-6790 (2009).
115. Wei CJ, Boyington JC, McTamney PM et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329(5995), 1060-1064 (2010).
116. Wei CJ, Xu L, Kong WP et al. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J. Virol. 82(13), 6200-6208 (2008). (Pubitemid 351875101)
117. Yang ZY, Wei CJ, Kong WP et al. Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science 317(5839), 825-828 (2007).
118. Oh HL, Akerstrom S, Shen S et al. An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses. J. Virol. 84(16), 8275-8286 (2010).
119. Fooks AR, Johnson N, Freuling CM et al. Emerging technologies for the detection of rabies virus: challenges and hopes in the 21st century. PLoS Negl. Trop. Dis. 3(9), e530 (2009).
120. Wright E, Hayman DT, Vaughan A et al. Virus neutralising activity of African fruit bat (Eidolon helvum) sera against emerging lyssaviruses. Virology 408(2), 183-189 (2010).
121. Wright E, McNabb S, Goddard T et al. A robust lentiviral pseudotype neutralisation assay for in-field serosurveillance of rabies and lyssaviruses in Africa. Vaccine 27(51), 7178-7186 (2009).
122. Wright E, Temperton NJ, Marston DA, McElhinney LM, Fooks AR, Weiss RA. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. J. Gen. Virol. 89(Pt 9), 2204-2213 (2008).
123. Chan SY, Speck RF, Ma MC, Goldsmith MA. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J. Virol. 74(10), 4933-4937 (2000). (Pubitemid 30237927)
124. Wool-Lewis RJ, Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J. Virol. 72(4), 3155-3160 (1998). (Pubitemid 28175558)
125. Ogino M, Ebihara H, Lee BH et al. Use of vesicular stomatitis virus pseudotypes bearing hantaan or seoul virus envelope proteins in a rapid and safe neutralization test. Clin. Diagn. Lab. Immunol. 10(1), 154-160 (2003). (Pubitemid 36133843)
126. Tamin A, Harcourt BH, Lo MK et al. Development of a neutralization assay for Nipah virus using pseudotype particles. J. Virol. Methods 160(1-2), 1-6 (2009).
127. Fukushi S, Mizutani T, Saijo M et al. Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV. J. Med. Virol. 78(12), 1509-1512 (2006). (Pubitemid 44672490)
128. Temperton NJ, Chan PK, Simmons G et al. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg. Infect. Dis. 11(3), 411-416 (2005). (Pubitemid 40315726)
129. Garcia JM, Lagarde N, Ma ES, de Jong MD, Peiris JS. Optimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle-based serological assay. J. Clin. Virol. 47(1), 29-33 (2010).
130. Kong WP, Hood C, Yang ZY et al. Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc. Natl Acad. Sci. USA 103(43), 15987-15991 (2006). (Pubitemid 44657579)
131. Capecchi B, Fasolo A, Albertini I et al. Use of pseudotyped particles expressing Influenza A/Vietnam/1194/2004 hemagglutinin in neutralization assays. In:Options for the Control of Influenza VI. Katz JM (Ed.).International Medical Press, London, UK, 303-305 (2008).
132. Oh DY, Barr IG, Mosse JA, Laurie KL. MDCK SIAT-1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J. Clin. Microbiol. 46(7), 2189-2194 (2008).
133. Buchy P, Vong S, Chu S et al. Kinetics of neutralizing antibodies in patients naturally infected by H5N1 virus. PLoS ONE 5(5), e10864 (2010).
134. Cavailler P, Chu S, Ly S et al. Seroprevalence of anti-H5 antibody in rural Cambodia, 2007. J. Clin. Virol. 48(2), 123-126 (2010).
135. Inoue E, Wang X, Osawa Y, Okazaki K. Full genomic amplification and subtyping of influenza A virus using a single set of universal primers. Microbiol. Immunol. 54(3), 129-134 (2010).
136. Stech J, Stech O, Herwig A et al. Rapid and reliable universal cloning of influenza A virus genes by target-primed plasmid amplification. Nucleic Acids Res. 36(21), e139 (2008).